Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 734-739

  Balli, Eleni P ^a   Venetis, Chris A ^a   Miyakis, Spiros ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b WOLLONGONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID;

ANTIBIOTIC THERAPY; BACTEREMIA; COMPARATIVE STUDY; DATA BASE; EMBASE; ENTEROCOCCAL INFECTION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG COMBINATIONS; ENTEROCOCCUS; HUMANS; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84893506154     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01289-13     Document Type: Review

References (34)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. http://dx.doi.org/10.1086/421946.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011. http://dx.doi.org/10.1086/591861.
3. European Centre for Disease Prevention and Control. 2010. Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm, Sweden. http://ecdc.europa.eu/en/publications/Publications/1011-SUR-annual-EARS- Net-2009.pdf.
4. Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, Yong D, Choi JY, Song YG, Lee K, Kim JM. 2009. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J. Infect. 58:182-190. http://dx.doi.org/10.1016/j.jinf.2009.01.013.
5. McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW. 2011. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol. Infect. 139:1342-1350. http://dx.doi.org/10.1017/S0950268810002475.
6. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE. 2012. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J. Hosp. Med. 7:243-248. http://dx.doi.org/10.1002/jhm. 994.
7. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. 2005. Comparison of mortality associated with vancomycin-resistant and vancomycinsusceptible enterococcal bloodstream infections: a meta-analysis. Clin. Infect. Dis. 41:327-333. http://dx.doi.org/10.1086/430909.
8. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. 2007. Antimicrobial resistance and molecular epidemiology of vancomycinresistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58:163-170. http://dx.doi.org/10.1016/j.diagmicrobio.2006.12.022.
9. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrugresistant enterococcal infections. Clin. Microbiol. Infect. 16:555-562. http://dx.doi.org/10.1111/j.1469-0691.2010.03214.x.
10. Rubinstein E, Prokocimer P, Talbot GH. 1999. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J. Antimicrob. Chemother. 44(Suppl A):37-46. http://dx.doi.org/10.1093/jac/44.suppl-1.37.
11. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. http://dx.doi.org/10.1128/AAC.45.2.454-459.2001.
12. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. 2003. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob. Agents Chemother. 47:3760-3763. http://dx.doi.org/10.1128/AAC.47.12.3760-3763.2003.
13. Kvirikadze N, Suseno M, Vescio T, Kaminer L, Singh K. 2006. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand. J. Infect. Dis. 38:290-292. http://dx.doi.org/10.1080/00365540500434687.
14. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. 2007. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J. Infect. 54:567-571. http://dx.doi.org/10. 1016/j.jinf.2006.11.007.
15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1-45. http://dx.doi.org/10.1086/599376.
16. Crank CW, Scheetz M, Brielmaier B, Rose W, Patel G, Ritchie D, Segreti J. 2008. Comparison of daptomycin (D) vs. linezolid (L) for vancomycin-resistant enterococcal bacteremia (VRE), abstr K-3442. Abstr. Joint 48th Intersci. Conf. Antimicrob. Agents Chemother. 46th Infect. Dis. Soc. Am. Annu. Meet.
17. Locastro LG, Perez ME, Marino EA, Abrardo LA, Gallagher JC. 2008. Comparison of linezolid (LZD) and daptomycin (DAP) for vancomycinresistant Enterococcus bacteremia (VREB), abstr K-3440. Abstr. Joint 48th Intersci. Conf. Antimicrob. Agents Chemother. 46th Infect. Dis. Soc. Am. Annu. Meet.
18. Mave V, Hasbun R, Garcia-Diaz J. 2007. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?, abstr 1090. Abstr. 45th Annu. Meet. Infect. Dis. Soc. Am.
19. McKinnell JA, Patel M, Shirley RM, Kunz DF, Baddley JW. 2009. Clinical outcomes with linezolid and daptomycin for the treatment of VRE bacteremia, abstr K-1603. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
20. Erlandson KM, Sun J, Iwen PC, Rupp ME. 2008. Impact of the morepotent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin. Infect. Dis. 46:30-36. http://dx.doi.org/10.1086/523588.
21. Bio LL, Perez ME, MacDougall C, Gallagher JC. 2011. Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia. Infect. Dis. Clin. Pract. 19:343-347. http://dx.doi.org/10.1097/IPC. 0b013e31822b7f6e.
22. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J. 2010. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin. Ther. 32:1713-1719. http://dx.doi.org/10.1016/ j.clinthera.2010.09.008.
23. Dubrovskaya Y, Kubin CJ, Furuya EY. 2008. Daptomycin (D) compared to linezolid (L) for primary treatment of vancomycin-resistant enterococcal bacteremia (VREB), abstr K-3443. Abstr. Joint 48th Intersci. Conf. Antimicrob. Agents Chemother. 46th Infect. Dis. Soc. Am. Annu. Meet.
24. El-Lababidi RM, Topal J, Tsukerman M. 2007. Daptomycin and linezolid in the treatment of vancomycin-resistant enterococcal bacteremia: a retrospective analysis of treatment outcomes, abstr 1095. Abstr. 45th Annu. Meet. Infect. Dis. Soc. Am.
25. Furuya EY, Kubin C, Yin M, Lowy FD, Della-Latta P, Hammer S. 2005. Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia, abstr K-2116. bstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
26. Kraft S, MacKler E, Schlickman P, Welch K, Depestel DD. 2011. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer 19:1969-1974. http://dx.doi.org/10.1007/s00520-010-1038-z.
27. Marion C, Kennedy L, High K. 2008. Daptomycin or linezolid in the treatment of vancomycin-resistant enterococcal bacteremia in neutropenic cancer patients, abstr L-2120. Abstr. Joint 48th Intersci. Conf. Antimicrob. Agents Chemother. 46th Infect. Dis. Soc. Am. Annu. Meet.
28. Mave V, Garcia-Diaz J, Islam T, Hasbun R. 2009. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J. Antimicrob. Chemother. 64:175-180. http://dx.doi.org/10.1093/jac/dkp154.
29. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234. http://dx.doi.org/10.1093/cid/ciq113.
30. King ST, Usery JB, Holloway K, Koeth L, Cleveland KO, Gelfand MS. 2011. Successful therapy of treatment-emergent, non-clonal daptomycinnon-susceptible Enterococcus faecium infections. J. Antimicrob. Chemother. 66:2673-2675. http://dx.doi.org/10.1093/jac/dkr343.
31. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin-and cationic host defense peptide-mediated killing of ampicillin-and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:838-844. http://dx.doi.org/10.1128/AAC.05551-11.
32. Crompton JA, North DS, McConnell SA, Lamp KC. 2009. Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J. Chemother. 21:414-420. http://dx.doi.org/10.1179/joc.2009.21.4.414.
33. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. 2012. Evaluation of standard-and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/ pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 56:3174-3180. http://dx.doi.org/10.1128/AAC.06439-11.
34. Steenbergen JN, Mohr JF, Thorne GM. 2009. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J. Antimicrob. Chemother. 64:1130-1138. http://dx.doi.org/10. 1093/jac/dkp346.